Hyperfine Inc

Hyperfine Inc (HYPR) Stock Analysis

$0.833

-0.012 (-1.44%)At close

Loading chart…
High
0.857
Open
0.852
VWAP
0.84
Vol
326.41K
Mkt Cap
68.77M
Low
0.831
Amount
274.34K
EV/EBITDA, TTM
-1.07

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

AI analysis of Hyperfine Inc (HYPR)

sell

Hyperfine Inc (HYPR) is not a good buy right now due to its current price of $0.8332, which is significantly below the analyst price target of $2. Additionally, the RSI is at a very low 19.399, indicating oversold conditions, but the overall negative momentum and insider selling of 6311.17% raise concerns. The main risk is the company's ongoing losses, with a net income of -9,298,000 USD in Q2 2026, which suggests financial instability despite some revenue growth.

Valuation Metrics

The current forward P/E ratio for Hyperfine Inc (HYPR) is 0.00, compared to its 5-year average forward P/E of -2.07.

Forward P/E

Overvalued
5Y Average P/E
-2.07
Current P/E
0.00
Overvalued
-0.97
Undervalued
-3.17

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.82
Current EV/EBITDA
-1.07
Overvalued
1.00
Undervalued
-2.64

Forward P/S

Fair
5Y Average P/S
7.53
Current P/S
3.41
Overvalued
15.77
Undervalued
-0.71

Whales holding HYPR

A

Alphabet Inc.

+ HoldingHYPR

-43.87%

3M Return

Events Timeline

2026-08-26 (ET)

08:30:00

Hyperfine Announces NEURO PMR Study Results

2026-08-20 (ET)

08:30:00

Hyperfine Receives FDA Clearance for Optive AI Software Update

2026-08-06 (ET)

16:30:00

Hyperfine Q2 Revenue at $3.904M, Below Consensus

2026-07-01 (ET)

08:30:00

Hyperfine Launches Next-Gen Swoop System in Europe

2026-06-22 (ET)

08:30:00

Hyperfine Forms Neurosurgery Advisory Council

News

HYPR FAQ — answered by Alphio AI

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Hyperfine Inc (HYPR) is not a good buy right now due to its current price of $0.8332, which is significantly below the analyst price target of $2. Additionally, the RSI is at a very low 19.399, indicating oversold conditions, but the overall negative momentum and insider selling of 6311.17% raise concerns. The main risk is the company's ongoing losses, with a net income of -9,298,000 USD in Q2 2026, which suggests financial instability despite some revenue growth.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started